Prostate-specific antigen and detection of prostate cancer: What we have we learned and what should we recommend for screening?

Current Treatment Options in Oncology

Volumn 7, Issue 5, 2006, Pages 337-345

  Amling, Christopher L ^a  

^a Alabama   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; CANCER MORTALITY; CANCER SCREENING; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY;

CLINICAL TRIALS; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33748375542     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0001-1     Document Type: Review

References (47)

1. Hernandez J, Thompson IM: Prostate-specific antigen: review of the validation of the most commonly used cancer biomarker. Cancer 2004, 101:894-904.
2. Catalona WJ, Smith DS, Ratliff TL, et al,: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324:1156-1161.
3. Catalona WJ, Smith DS, Ratliff TL, et al.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993, 270:948-954.
4. Ross LE, Coates RJ, Breen N, et al.: Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004, 38:732-744.
5. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995, 273:289-294.
6. Punglia RS, D'Amico AV, Catalona WJ, et al.: Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen, N Engl J Med 2003, 349:335-342.
7. Stamey TA, Johnstone IM, McNeal JE, et al.: Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology; prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002, 167:103-111.
8. Oesterling JE, Jacobsen SJ, Chute CG, et al.: Serum prostate specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993, 270:860-864.
9. Catalona WJ, Hudson MA, Scardino PT et al.: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994, 152:2037-2042.
10. Benson MC, Whang IS, Olsson CA, et al.: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992, 147:817-821.
11. Catalona WJ, Richie JP, deKernion JB, et al.: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994, 152:2031-2036.
12. Carter HB, Pearson JD, Metter EJ, et al.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992, 267:2215-2220.
13. Partin AW, Brawer MK, Bartsch G, et al.: Complexed prostate specific antigen improves specificity for prostate cancer detection; results of a prospective multicenter clinical trial. J Urol 2003, 170:1787-1791.
14. Catalona WJ, Bartsch G, Rittenhouse HG, et al.: Serum pro-prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003, 170:2181-2185.
15. Liu S, Lee IM, Linson P, et al.: A prospective study of physical activity and risk of prostate cancer in US physicians. Int J Epidemiol 2000, 29:29-35.
16. Draisma G, Boer R, Otto SJ, et al.: Lead times and over-detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868-878.
17. Tarone R, Chu K, Brawley O: Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000, 11:167-170.
18. Bartsch G, Horninger W, Klocker H, et al.: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001, 58:417-424.
19. Labrie F, Candas B, Dupont A, et al.: Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999, 38:83-91.
20. Andriole GL, Levin DL, Crawford D, et al.: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005, 97:433-438.
21. de Koning HJ, Liem MK, Baan CA, et al.: Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomized Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002, 98:268-273.
22. McGregor M, Hanley JA, Boivin JF, et al.: Screening for prostate cancer: estimating the magnitude of over-detection. CMAJ 1998, 159:1368-1372.
23. Zappa M, Ciatto S, Bonardi R, et al.: Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998, 9:1297-1300.
24. Etzioni R, Penson DF, Legler JM, et al.: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002, 94:981-990,
25. Gann PH: Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology 1997, 8:117-120.
26. Etzioni R, Cha R Feuer EJ, et al.: Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998, 148:775-785.
27. Ohori M, Wheeler TM, Dunn JK, et al.: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994, 152:1714-1720.
28. Stamey TA, Freiha FS, McNeal JE, et al.: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993, 71:933-938.
29. Epstein JI, Carmichael M, Partin AW, et al.: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993, 149:1478-1481.
30. Loeb S, Gonzalez CM, Roehl KA, et al.: Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006, 175:902-906.
31. Wilson SS, Crawford ED: Screening for prostate cancer: current recommendations. Urol Clin N Am 2004, 31:219-226.
32. Thompson IM, Pauler DK, Goodman PJ, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter. N Engl J Med 2004, 350:2239-2246.
33. Thompson IM, Ankerst DP, Chi C, et al.: Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005, 294:66-70.
34. Smith RA, Cokkinides V, Eyre HJ, et al.: American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2006, 56:11-25.
35. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology 2000, 14:267-272.
36. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. http//www.nccn.org/professionals/physician_gls/f_guidelines. Accessed March 15, 2006.
37. Zoorob R, Anderson R, Cefalu C, et al.: Cancer screening guidelines. Am Fam Physician 2001, 63:1101-1112.
38. Harris R, Lohr KN: Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:917-929.
39. Boyle P: Screening for prostate cancer: have you had your cholesterol measured? BJU Int 2003, 92:191-199.
40. Ross KS, Carter HB, Pearson JD, et al.: Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000, 284:1399-1405.
41. Crawford ED, Pinsky PF, Chia D, et al.: Prostate specific antigen changes as related to the initial prostate specific antigen: data from the Prostate, Lung, Colorectal and Ovarian Cancer screening trial. J Urol 2006, 173:1286-1290.
42. Catalona WJ, Loeb S, Han M: Viewpoint: expanding prostate cancer screening. Ann Intern Med 2006, 144:441-443.
43. Presti JC, O'Dowd GJ, Miller MC, et al.: Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003, 169:125-129.
44. Alibhai SM, Naglie G, Nam R, et al.: Do older men benefit from curative therapy for localized prostate cancer? J Clin Oncol 2003, 21:3318-3327.
45. Welch HG, Albertson PC, Nease RF, et al.: Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 1996, 124:577-584.
46. Etzioni RD, Howlander N, Shaw PA, et al.: Long-term effects of finasteride on prostate-specific antigen levels: results from the Prostate Cancer Prevention Trial. J Urol 2005, 174:877-881.
47. Anternor JA, Roehl KA, Eggener SE, et al.: Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease. Urology 2005, 66:156-160.